Market research
AQST Aquestive Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 585M
- P/E ratio
- Not available
- Analyst target
- 9.3333
- Dividend yield
- Not available
- Beta
- 1.43
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US03843E1047
- Market cap
- 585M
- P/E ratio
- Not available
- Analyst target
- 9.3333
- Dividend yield
- Not available
- Beta
- 1.43
About
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AQST discussion.
5 years, 4 months ago
Aquestive Therapeutics, Inc is currently in a long term downtrend where the price is trading 30.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.8.
Aquestive Therapeutics, Inc's total revenue sank by 56.5% to $7M since the same quarter in the previous year.
Its net income has dropped by 61.2% to $-20M since the same quarter in the previous year.
Finally, its free cash flow fell by 29.0% to $-14M since the same quarter in the previous year.
Based on the above factors, Aquestive Therapeutics, Inc gets an overall score of 1/5.